Safety and effectiveness of iliac artery stenosis treatment using percutaneous radial or brachial access: 30-day and 12-month outcomes from the IRBIS registry

经皮桡动脉或肱动脉入路治疗髂动脉狭窄的安全性和有效性:来自IRBIS注册研究的30天和12个月结果

阅读:1

Abstract

INTRODUCTION: Radial or brachial access for endovascular treatment of peripheral arterial disease may reduce access site complications and avoid the need for post-procedure immobilization. AIM: This study evaluated in-hospital, 30-day, and 12-month outcomes for iliac artery lesion treatment with these access types. MATERIAL AND METHODS: The study retrospectively included 109 patients, 67% males, aged 38-88 years, with chronic lower limb ischemia and atherosclerotic lesions in the iliac arteries. Endovascular treatment was performed via radial or brachial access in 22% and 78% of cases. Iliac artery occlusions, subocclusions, and significant stenoses were present in 11%, 24%, and 65% of patients. We collected data on demographics, comorbidities, procedural details, adverse events, and outcomes. RESULTS: During the hospital stay and 30-day follow-up, there were no deaths, amputations, or reinterventions. Technical success was achieved in 100% of cases, with no conversions to femoral access required. The overall complication rate related to the access site was 4.6%, with 3.6% of complications necessitating local surgical intervention. Notably, there was one minor ischemic stroke and one distal embolization during using right brachial access. All reported access site complications were associated with brachial access. The average time to discharge after the procedure was 1.2 days. At 12 months, the target lesion revascularization rate was 3.7%. CONCLUSIONS: Radial or brachial access was a safe alternative to femoral access for endovascular procedures in the iliac arteries. Using left-side radial or brachial access enabled 100% technical success.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。